Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "FDA"


25 mentions found


Posts shared online claim that vaccinated passengers testing positive for the COVID-19 virus on a cruise ship is an indication that COVID-19 vaccines do not work. Passengers testing positive on a cruise ship that requested they be vaccinated is not proof that the vaccines do not work. In comparison, the COVID-19 vaccines appear to be more effective than the seasonal influenza vaccine, according to Centers for Disease Control and Prevention data here . Fully vaccinated passengers testing positive for the COVID-19 virus on a cruise ship is not proof that the vaccines do not work. COVID-19 vaccines significantly reduce the risk for contracting the virus as well as the risk for severe illness and hospitalization.
Persons: , “ It’s, “ That’s, , BioNTech, Johnson, Read Organizations: Royal, Pfizer, Moderna, Janssen, Food and Drug Administration, FDA, CDC, The Washington, for Disease Control, Reuters Locations: Royal Caribbean, United States, Moderna, COVID
University Vaccine Mandates Violate Medical Ethics
  + stars: | 2021-06-14 | by ( Aaron Kheriaty | Gerard V. Bradley | ) www.wsj.com + 0.00   time to read: +3 min
Schools have for decades required vaccination against infectious diseases, but these mandates are unprecedented—and unethical. Never before have colleges insisted that students or employees receive an experimental vaccine as a condition of attendance or employment. Even soldiers, whose rights are constrained when they join the service, aren’t being compelled to take a Covid vaccine. The FDA has issued such authorizations for three Covid vaccines, but it hasn’t fully approved any of them. Colleges’ vaccine mandates also ignore the huge number of students—thousands of them at Notre Dame—who have already recovered from Covid infection, and who thus possess natural immunity, which studies have suggested is more robust and durable than vaccine immunity.
Persons: aren’t, hasn’t, Notre Dame —, vaccinating Organizations: Covid, Food and Drug Administration, FDA, Notre Dame, Pfizer, FDA’s, Products Advisory, Colleges Locations: United States
U.S. FDA declines to approve Avenue's IV formulation of non-opioid painkiller
  + stars: | 2021-06-14 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
REUTERS/Andrew Kelly/File Photo(Reuters) -Avenue Therapeutics Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its intravenous formulation of non-opioid painkiller tramadol for a second time, sending its shares tumbling about 38%. The FDA has been pushing drugmakers to develop alternatives to opioid-based painkillers, as the United States grapples with the menace of opioid addiction. The health regulator in October declined to approve the intravenous formulation of the painkiller, stating it was not safe for the intended population. H.C. Wainwright analyst Joseph Pantginis, however, says that IV tramadol could still have a path forward. Tramadol was approved in the United States in 1995 as a non-controlled analgesic, under the trade name of Ultram, to be sold by drugmaker Johnson & Johnson.
Persons: Andrew Kelly, tramadol, Wainwright, Joseph Pantginis, Tramadol, drugmaker Johnson, Johnson Organizations: Food and Drug Administration, FDA, REUTERS, Therapeutics Inc, U.S . Food, Drug Administration Locations: White Oak , Maryland, U.S, United States
U.S. FDA declines to approve Avenue's IV formulation of painkiller
  + stars: | 2021-06-14 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +1 min
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The health regulator in October declined to approve the intravenous formulation of the painkiller, stating it was not safe for the intended population. The agency said on Monday the delayed and unpredictable onset of analgesia - relief from pain - with intravenous (IV) tramadol did not support its benefit as a monotherapy to treat patients with acute pain. H.C. Wainwright analyst Joseph Pantginis, however, says that IV tramadol could still have a path forward. Tramadol was approved in the United States in 1995 as a non-controlled analgesic, under the trade name of Ultram, to be sold by drugmaker Johnson & Johnson.
Persons: Andrew Kelly, tramadol, Wainwright, Joseph Pantginis, Tramadol, drugmaker Johnson, Johnson Organizations: Food and Drug Administration, FDA, REUTERS, Therapeutics Inc, U.S . Food, Drug Administration Locations: White Oak , Maryland, U.S, United States
The Maryland-based biotech company Novavax reported Monday that its experimental Covid-19 vaccine is safe and 100 percent effective against moderate to severe disease. The company has already completed a Phase 3 trial in the U.K., but the U.S. trial results are required to apply for emergency use authorization in this country. The Novavax vaccine is given in two doses, 21 days apart. The Pfizer, Moderna and Johnson & Johnson vaccines all work by providing genetic instructions for the body to build the coronavirus's spike protein, which the immune system learns to recognize and fight. The Novavax vaccine can be stored in standard refrigerator temperatures.
Persons: Novavax, Biden, Joe Biden, William Schaffner, Dr, David Hirschwerk, Robert Wood Johnson, Julie Morita, Morita, Johnson Organizations: Food and Drug Administration, Vanderbilt University Medical Center, for Disease Control, Alpha, Robert Wood Johnson Foundation, Chicago Department of Public Health, NBC, Trump, FDA, Johnson, Pfizer, BioNTech, Moderna, CDC, Twitter, Facebook Locations: Maryland, U.S, Mexico, Nashville , Tennessee, Manhasset , New York, Brazil, South Africa, India, Moderna
Novavax Covid-19 Vaccine Is 90% Effective in Key Study
  + stars: | 2021-06-14 | by ( Peter Loftus | ) www.wsj.com + 0.00   time to read: +10 min
Despite the study results, Novavax said it needs much of that time to ensure that its manufacturing processes meet regulatory standards. Novavax started its late-stage, or Phase 3, trial of the Covid-19 vaccine in late December. Novavax said that the vaccine was 93.2% effective combined against the variants of concern and variants of interest in the study. One challenge conducting the study, Novavax said, was the availability of authorized vaccines. In all, about 5,000 people dropped out of the study, Novavax said, meaning the Covid-19 cases that were used to determine efficacy occurred among the remaining 25,000 study subjects, Dr. Glenn said.
Persons: Novavax, , Gregory Glenn, T.J, Kirkpatrick, Stanley Erck, Erck, Biden, Johnson, wasn’t, Glenn, Peter Loftus Organizations: Novavax Inc, Wall, Health, U.S . Food, Drug Administration, Pfizer Inc, Moderna Inc, Pfizer, BioNTech, Moderna, FDA, D.C, GlaxoSmithKline, Johnson, AstraZeneca, National Institutes of Health, peter.loftus Locations: U.S, Mexico, Gaithersburg, Md, China, Covid, Washington, Chile, Brazil, India
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Additionally, the two-dose vaccine was found to be 100% effective in preventing moderate and severe disease and 93% effective against some variants, Novavax said. The new data comes as federal officials say the U.S. has more than enough doses of Covid vaccines to finish vaccinating the entire American population. It's possible the U.S. could end up donating doses of the Novavax vaccine. Novavax said Monday it remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the fourth quarter of 2021.
Persons: Novavax, Dr, Gregory Glenn, Johnson, Biden Organizations: Biotech, Food and Drug Administration, Alpha, FDA, Pfizer, BioNTech, Moderna, Johnson, Centers for Disease Control, U.S, White House, Defense, AstraZeneca, Sanofi, Novavax Locations: United States, Mexico, U.S
U.S. stock futures were flat Monday after the S&P 500 eked out another record close Friday. The S&P 500 rose 0.4% for the week, notching a three-week winning streak. The Nasdaq 's gain Friday put the tech-heavy index within 0.5% of its record close in late April. The Dow 's slight advance Friday inched the 30-stock average less than 1% closer to last month's record close. (CNBC)AstraZeneca's (AZN) Covid vaccine has a favorable risk/reward profile for all age groups and particularly for those 60 years and older, according to the head of the European Medicines Agency's Covid-19 task force.
Persons: Dow, Bitcoin, Elon Musk, Tesla, Steve Burns, Julio Rodriguez, Lordstown, Novavax, Marco Cavaleri, Boris Johnson, Joe Biden, Biden, Donald Trump, Vladimir Putin, Naftali Bennett, Benjamin Netanyahu, Netanyahu, Jeff Bezos, Mark, Ernie ’, Bert ’ Organizations: Nasdaq, Dow, CNBC, bitcoin, Lordstown Motors, Biotech, FDA, European Medicines, NATO, Sunday, Royal, Shell, Reuters, Washington, Nintendo, Microsoft, Ubisoft, Enix, Origin, Amazon, Shepard Locations: Mexico, India, Covid, Belgium, Brussels, China, Russia, United States, Europe, Geneva, Switzerland, Texas
With widespread US vaccinations, the company plans to refocus on its clinical-genomics business, even as it maintains coronavirus testing capabilities. In June, the startup raised a $50 million funding round, which it plans to use to further its clinical-genomics business, as well as its efforts in coronavirus testing and tracking. A Helix lab worker pours reagent into one of the machines that automate the distribution of samples. In the lab space dedicated to coronavirus testing, a team of workers check each bagged sample for leakage and scan them into Helix's barcode system. By April, the CDC announced that the Alpha variant had become the dominant coronavirus variant in the US.
Persons: Helix's, James Lu, Alpha —, Jade Fulce, Lu, Kedar Karkare, Helix, , overburdened, Marc Laurent, Laurent, William Lee, Lee, he's Organizations: CDC, Helix, Alpha, ., National Institutes of Health, for Disease Control, San Mateo, San Diego . Research, Quest Diagnostics, San Diego, Scripps Research, Cell, FDA Locations: Bay, San Diego, San Mateo , California, United States
Biotech Rally Sparked by Alzheimer’s Drug Has Staying Power
  + stars: | 2021-06-13 | by ( Charley Grant | ) www.wsj.com sentiment -0.99   time to read: +1 min
The Food and Drug Administration gave the green light to Biogen ’s drug Aduhelm on Monday. Eli Lilly , which has a similar Alzheimer’s drug under development, rallied 10% on Monday. Alzheimer’s has been a particularly confounding corner of drug research for decades; a 2018 analysis found that 146 experimental drugs had failed in clinical trials over the past 20 years. The FDA’s decision to approve Aduhelm despite significant concerns over its efficacy changes the outlook for those research efforts. Even the perception of a more forgiving regulatory agency is enough to spark fresh enthusiasm for biotech, and not only for companies with an Alzheimer’s program.
Persons: Eli Lilly, Alzheimer’s Organizations: Drug Administration, FDA, Nasdaq
A federal judge threw out a lawsuit filed by over 100 Houston Methodist employees. The judge said the workers were not being forced or coerced to take a vaccine. A federal judge tossed out a lawsuit from more than 100 hospital employees who sued Houston Methodist over its policy requiring all staff to be vaccinated against COVID-19. The hospital has already suspended 178 workers who have missed the vaccine deadlineThe exterior of the Houston Methodist Hospital is seen on June 09, 2021 in Houston, Texas. In a statement to Insider, Houston Methodist's president and CEO, Dr. Marc Boom, praised the hospital system's 26,000 employees who received the vaccine.
Persons: Lynn Hughes, Hughes, Jared Woodfill, Woodfill, Brandon Bell, Johnson, Marc Boom Organizations: Houston Methodist, COVID, Houston Methodist Hospital, Getty, Brandon Bell Houston Methodist, US Food and Drug Administration, FDA, Pfizer, BioNTech, Moderna, Houston Locations: Nuremberg, Houston , Texas
S.Africa to analyse J&J vaccines made at U.S. plant halted over error
  + stars: | 2021-06-12 | by ( ) www.reuters.com sentiment -1.00   time to read: +2 min
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic//File PhotoSouth African health inspectors will carry out further checks on a batch of Johnson & Johnson (JNJ.N) COVID-19 vaccines following a contamination error earlier this year at the U.S. plant where the doses were produced, the health ministry said. "There is now a real possibility that they may not be, however this is for the regulator to rule on," a ministry statement said. read moreManufacturing at the Baltimore plant owned by Emergent Biosolutions Inc (EBS.N) was halted in April after the discovery that ingredients from AstraZeneca's (AZN.L) COVID-19 vaccine, also being produced at the plant at the time, had contaminated a batch of J&J's vaccine. read moreAn inspection by the FDA also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant.
Persons: Johnson, Dado Ruvic Organizations: REUTERS, Johnson, U.S . Food, Drug Administration, FDA, Emergent Biosolutions Inc, Thomson Locations: U.S, South Africa, Baltimore
In this article LLYBIIBAduhelm by Biogen Source: BiogenThe FDA's approval of Biogen's Alzheimer's drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen. One immediate challenge facing other teams working on a wider Alzheimer's drug pipeline, he said in a recent video call, would be to retain participants in ongoing trials, let alone attract new ones. "In most cases," he explained, many Alzheimer's sufferers will drop out of other drug studies to pursue treatment with the newly approved Aduhelm. The controversy surrounding the Biogen drug, including its potential cost, comes against a landscape of massive, unmet need for dementia treatment and a disease that costs the U.S. as much as $259 billion annually. That is why some dementia drug experts are focusing on the renewed attention and fresh financing rather than the potential negatives from the Biogen approval, according to Dr. Jeffrey Cummings, a neurologist at the University of Nevada, Las Vegas, who publishes an annual review of the Alzheimer's drug development pipeline.
Persons: Aduhelm, Dr, Paul Aisen, Aisen, Aaron Kesselheim, aducanumab, , Boehringer, Biogen, Jeffrey Cummings, Cummings, Eli Lilly's donanemab, Roche's, Eli Lilly, David Ricks, Biogen's Aduhelm, Lilly Organizations: Biogen, Therapeutic Research, USC, and Drug Administration, FDA, Harvard Medical School, Pfizer, Alzheimer's Association, University of Nevada, National Institutes of Health, pharma, CNBC Locations: San Diego, Las Vegas
The Food and Drug Administration has told Johnson & Johnson to discard about 60 million doses of its Covid-19 vaccine that were produced at a troubled plant in Baltimore, according to two people familiar with the matter. But the FDA plans to allow Johnson & Johnson to distribute 10 million doses that were manufactured at the same facility, according to the two people familiar with the decision. The FDA’s decision to tell Johnson & Johnson to dump the vaccines was first reported by the New York Times. Following the inspection, the agency required Johnson & Johnson to take full control of the facility. Friday’s action followed a move earlier in the week by the FDA to extend the shelf life of Johnson & Johnson doses from three months to four and a half months.
Persons: Johnson, Dr, Peter Marks, ” Kathy Wengel, Organizations: Drug Administration, FDA, Johnson, FDA’s, Biologics, Research, New York Times, AstraZeneca, NBC News Locations: Baltimore, United States
Vaccination rates for children 12 to 17 have surged in the Northeast and lagged in the South, one month since the first Covid-19 vaccines were cleared for ages 12 and up, according to an NBC News analysis. And in Connecticut, Maine, Maryland, New Hampshire and Rhode Island, more than 40 percent of 12- to 17-year-olds have received one shot. Just over 7 percent of Mississippi 12- to 17-year-olds have received their first dose, and less than 10 percent of that age group in Louisiana. In the Midwest, teenage Covid-19 vaccination rates for the first dose hover around 25 percent. NBC News calculated teenage vaccination rates by subtracting first dose vaccinations for adults 18 and up from those 12 and up.
Persons: David Kimberlin, Kimberlin, They're, Covid, Natasha Burgert, Rochelle Walensky, Walensky Organizations: NBC, University of Alabama, Pfizer, Centers for Disease Control, Twitter, Facebook Locations: Vermont, Massachusetts, Connecticut , Maine , Maryland , New Hampshire, Rhode Island, Mississippi, Louisiana . Alabama, Birmingham, Michigan, Wisconsin, Nebraska, Ohio, Missouri, Kansas City, California
WASHINGTON—The Food and Drug Administration is expected as early as Friday to clear for export 10 million doses of Johnson & Johnson ’s Covid-19 vaccine from a Baltimore factory that had been beset by contamination problems, according to people familiar with the situation. However, the agency has notified J&J that approximately 60 million doses of vaccine substance were not satisfactory and can’t be used, according to one of the people, a senior U.S. official. That leaves potentially 60 million more J&J doses that could get approved still. The release of the 10 million doses is expected to be the first of several steps to approve vaccine that was produced at the Baltimore plant run by Emergent BioSolutions Inc. before manufacture was halted by the FDA over quality shortfalls. The Emergent plant made vaccine for J&J and for AstraZeneca PLC, before an April 30 FDA inspection report concluded that the facility didn’t take proper measures to avoid cross-contamination between the two companies’ vaccine lines.
Persons: WASHINGTON, Johnson Organizations: Drug Administration, Johnson, The New York Times, Emergent BioSolutions Inc, FDA, Biden, AstraZeneca PLC Locations: Baltimore, U.S
For the first time in 18 years, the Food and Drug Administration approved a new medication for Alzheimer's on Monday. Partly because we've all been conditioned to see an Alzheimer's diagnosis as hopeless, so we avoid finding out until it critically hinders someone's ability to function. For instance, the new Alzheimer's drug, aducanumab, was tested on people with mild cognitive impairment or early stage dementia. Scientists are also increasingly referring to Alzheimer's disease as "Type 3 diabetes" because of its involvement with insulin resistance in the brain. How we depict Alzheimer's patients needs to change, too.
Persons: James Foster Jr, Brenda Foster, I've, Glen Campbell, Fans Organizations: Food and Drug Administration, FDA, National Institutes of Health
WASHINGTON—The Food and Drug Administration is making millions of Johnson & Johnson Covid-19 vaccine doses available for export from a Baltimore factory that had been beset by contamination problems. A review determined that two batches of vaccines produced at the Baltimore plant run by Emergent BioSolutions Inc. were suitable for use, the FDA said Friday. The two batches cleared for use will provide about 10 million doses, according to people familiar with the situation. About 60 million doses were rejected for potential contamination, one of these people said, confirming a report in the New York Times. With those rejections, there are about 120 million vaccine doses and unbottled substance made for J&J and AstraZeneca PLC at the Baltimore plant that could be cleared in coming weeks and be available for export, according to this person, a senior U.S. official.
Persons: WASHINGTON, Johnson, Johnson Covid, Organizations: Drug Administration, Emergent BioSolutions Inc, FDA, New York Times, J, AstraZeneca PLC Locations: Baltimore, U.S
A third member of an FDA expert panel has resigned over the agency's accelerated approval of a new Alzheimer's drug. A third member of a Food and Drug Administration expert panel has resigned over the approval of a controversial new Alzheimer's drug. In a resignation letter obtained by CNBC, Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said the agency's decision to approve Biogen's new Alzheimer's drug, Aduhelm, "was probably the worst drug approval decision in recent US history." "The FDA, in using the accelerated approval mechanism, they could not endorse any evidence of demonstrable clinical benefit. Neurologist Dr. Joel Perlmutter of Washington University in St. Louis also resigned from the panel on Monday.
Persons: Aduhelm, Aaron Kesselheim, Kesselheim, David Knopman, Insider's Allison DeAngelis, Knopman, Dr, Joel Perlmutter, Louis Organizations: FDA, Drug Administration, CNBC, Harvard Medical School, Drugs Advisory, Mayo Clinic, Washington University Locations: St
In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel's members have resigned in protest since the FDA decision was announced on Monday read more . Karlawish ran one of the trial sites for the Biogen drug. The FDA approval allows Biogen to sell its product over several years - with forecasts for potential annual sales reaching as high $10 billion to $50 billion - until the company completes a required follow-up study. FDA officials said other Alzheimer's drug developers cannot assume their therapies will be considered under the same framework.
Persons: Brian Snyder, Biogen, Jason Karlawish, Karlawish, Johns, Caleb Alexander, Alzheimer's, Alfred Sandrock, Sandrock, Peter Stein, Aduhelm, Eli Lilly, drugmakers, Patrizia Cavazzoni, Jim Shehan, Lowenstein Sandler, UsAgainstAlzheimer's Organizations: REUTERS, U.S . Food, Drug Administration, FDA, Penn Memory Center, Alzheimer's Association, New Drugs, Reuters, Roche Holding, FDA's Center, Drug, Institute for Clinical, Economic, Thomson Locations: Cambridge , Massachusetts, U.S, Philadelphia
The government has blocked any shipments of Johnson & Johnson's vaccine, health officials told the WSJ. States already have stockpiles of the single-dose J&J shot, and vaccination rates are falling. US state and federal health officials told The Journal that the Centers for Disease Control and Prevention (CDC) is banning states from ordering the J&J shot. The vaccine suspension comes after the Food and Drug Administration (FDA) on Thursday extended the shelf life of the J&J vaccine from three months to four-and-a-half months when refrigerated. States currently have excess doses of the J&J vaccine, and millions of the single-dose vaccines are set to expire in June.
Persons: Johnson, Johnson COVID, Illinois haven't, Keith Reed, J didn't Organizations: Johnson, Wall Street, for Disease Control, Prevention, Food and Drug Administration, FDA Locations: Michigan , Oklahoma, Illinois
Biogen's Alzheimer's drug stumbled through testing but will become available in the US for $56,000. The arrival of the first new Alzheimer's drug in two decades should have been a moment of celebration. Collier was diagnosed in 2008 with Alzheimer's disease and was part of a clinical trial at Brigham and Women's Hospital. Though Knopman was against Aduhelm's approval, he's come around to the idea that it might not spell disaster for other drug trials. Chief Medical Officer Hans Moebius led the research team that developed the last major Alzheimer's drug, Namenda, which was approved in 2003.
Persons: Dr, David Knopman, Knopman, Biogen, Charles W, Collier, Scott McGinnis, Suzanne Kreiter, Aduhelm, Michel Vounatsos, Ronny Gal, That's, Charles Flagg, Charles Krupa, Alzheimer's, James Brewer, Jefferies, Andrew Tsai, George Perry, Perry, Thomson, Michael Greicius, Caleb Alexander, John Dwyer, drugmakers, he's, who've, that's, Hans Moebius, Moebius isn't, Dwyer Organizations: US Food and Drug Administration, Mayo Clinic, FDA, Brigham, Women's, Boston Globe, Getty, Alzheimer's Association, Caring, for Clinical, Medicare's, Butler Hospital, Associated Press Medical, University of California, University of Texas, Thomson Reuters, University of Southern, New York Times, Athira Pharma Locations: Providence , Rhode Island, University of California San Diego, San Antonio, Mexico City, University of Southern California, Seattle
Former FDA chief Scott Gottlieb on post-vaccine heart inflammation symptoms
  + stars: | 2021-06-11 | by ( ) www.cnbc.com sentiment -0.98   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFormer FDA chief Scott Gottlieb on post-vaccine heart inflammation symptomsThere have been a higher-than-expected number of cases of heart inflammation in 16- to 24-year-olds after receiving their second dose of Pfizer’s or Moderna’s Covid-19 vaccines, the Centers for Disease Control and Prevention said Thursday, citing preliminary data from its vaccine safety monitor system. Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joined "Squawk Box" on Friday to discuss.
Persons: Scott Gottlieb Organizations: FDA, Centers for Disease Control, Prevention, Pfizer
I'm Lydia Ramsey Pflanzer, and this week in healthcare news:If you're new to this newsletter, sign up here. Know someone under 40 transforming the healthcare industry? Skye Gould/InsiderWow, I can't believe it was just this Monday that the Food and Drug Administration approved the first new Alzheimer's treatment in nearly two decades. Since the approval, doctors have started resigning from the FDA's expert panel — the one that voted against approving the drug. The weight-loss startup stunned the healthcare industry in May when it raised $540 million from investors including Silver Lake and Oak HC/FT.
Persons: I'm Lydia Ramsey Pflanzer, Let's, We're, Skye Gould, Allison DeAngelis, Shelby Livingston, clamoring, Allison, Andrew Dunn, , Megan Herbroth, Gabby Landsverk, It's, Megan, Gabby, Shelby, Morgan Stanley, Lydia Organizations: Insider Healthcare, and Drug Administration, FDA, Oak HC, Amazon, Walmart, Amazon VP Locations: Silver
Rare instances of heart inflammation in young people after receiving their second Covid vaccine dose require further inquiry, Dr. Scott Gottlieb told CNBC on Friday. Gottlieb said many questions remain about the connection between the heart inflammation and the Covid vaccines from Pfizer and Moderna. Gottlieb said what's not known yet is whether there's something specific about the vaccines that are causing heart inflammation. "Is this a more generalized inflammatory response from the vaccine that's localizing in the heart in some patients?" Roughly 141.5 million people in the U.S. have been fully vaccinated against Covid, according to CDC data.
Persons: Scott Gottlieb, Gottlieb, there's, Trump, what's, haven't Organizations: CNBC, Food and Drug Administration, Pfizer, Moderna, CDC, FDA, Centers for Disease Control, Covid Locations: U.S
Total: 25